Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2020-11-24 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors, their roles, and committee memberships. It focuses on governance structure and board composition without financial data or other report content. This matches the description of Board/Management Information (MANG), which covers announcements of changes or details about the company's board or senior management. The document is short and does not contain financial statements or other report types. Therefore, it is classified as MANG with high confidence.
2020-11-24 English
APPOINTMENT OF EXECUTIVE DIRECTOR
Board/Management Information Classification · 95% confidence The document is an announcement from the Board of Directors of CSPC Pharmaceutical Group Limited regarding the appointment of Dr. Jiang Hao as an executive director. It details his background, terms of appointment, remuneration, and compliance with listing rules. There is no financial data, no report attached or referenced, and the content focuses solely on management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3535 characters, which is relatively short but contains substantive information about management changes, not just a brief notice or report publication announcement. Therefore, the correct classification is MANG with high confidence.
2020-11-23 English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2020
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial report titled "Quarterly Results For the Nine Months Ended 30 September 2020" for CSPC Pharmaceutical Group Limited. It contains extensive financial data including revenue, profit, segment information, earnings per share, and business review for the nine-month period ending 30 September 2020. The document is unaudited but provides comprehensive financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, it should be classified as an Interim / Quarterly Report (IR). 9M 2020
2020-11-23 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited third quarterly results for the nine months ended 30 September 2020. It does not contain the actual financial results or detailed financial data, but merely announces the upcoming board meeting where such results will be approved. The document length is only 1326 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, announcements about board meetings and related scheduling fall under Regulatory Filings (RNS) if they do not contain substantive financial data or detailed report content. Therefore, this document should be classified as Regulatory Filings (RNS).
2020-11-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share issuances. It includes confirmations by a director regarding the authorization and compliance of the securities issued. The content focuses on share capital changes and related confirmations, which aligns with announcements about share capital changes rather than a full financial report or earnings release. The document is comprehensive and contains substantive data on share capital movements, not just a brief announcement or certification. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2020-11-04 English
VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1813 ORAL SOLUTIONS" OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of an innovative drug. It is an announcement of a regulatory milestone related to the company's product development, not a financial report, earnings release, or management discussion. The document is relatively short (2746 characters) and serves as a public disclosure of a significant event rather than a detailed report or presentation. It does not contain financial data, management changes, voting results, or legal proceedings. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.